Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: A pooled analysis of the PRISMA I and II randomized trials

Journal of Human Hypertension

Volumn 23, Issue 9, 2009, Pages 610-619

  Williams, B ^a   Lacourciere Y ^b   Schumacher, H ^c   Gosse, P ^d   Neutel, J M ^e  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b Ctr Hosp de l'Univ de Que   (Canada)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HÔPITAL SAINT ANDRÉ   (France)

^e Orange County Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAMIPRIL; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 69549116316     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.4     Document Type: Article

References (36)

1. Kario K. Morning surge and variability in blood pressure: A new therapeutic target? Hypertension 2005; 45: 485-486.
2. Kario K. Time for focus on morning hypertension: Pitfall of current antihypertensive medication. Am J Hypertens 2005; 18: 149-151.
3. Marfella R, Siniscalchi M, Nappo F, Gualdiero P, Esposito K, Sasso FC et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18: 308-318.
4. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; i: 795-797.
5. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-1322.
6. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP et al. Morning increase in onset of ischemic stroke. Stroke 1989; 20: 473-476.
7. Tanaka A, Kawarabayashi T, Fukuda D, Nishibori Y, Sakamoto T, Nishida Y et al. Circadian variation of plaque rupture in acute myocardial infarction. Am J Cardiol 2004; 93: 1-5.
8. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 2003; 107: 1401-1406.
9. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003; 42 (Suppl 1): S87-S91.
10. Gosse P, Lasserre R, Minifié C, Lemetayer P, Clementy J. Blood pressure surge on rising. J Hypertens 2004; 22: 1113-1118.
11. Prisant LM. Hypertension and chronotherapy: Shifting the treatment paradigm. Am J Hypertens 2001; 14: 277S-279S.
12. Mallion JM, Baguet JP, Siche JP, Tremel F, de Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens 1998; 16(Suppl 1): S75-S79.
13. Fujii J, Seki A. Compliance and compliance-improving strategies in hypertension: The Japanese experience. J Hypertens Suppl 1985; 3(1): S19-S22.
14. Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens 1997; 15: 205-221.
15. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-210.
16. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. Am J Hypertens 2004; 17: 347-353.
17. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
18. Williams B, Gosse P, Lowe L, Harper R, PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193-200.
19. Lacourcière Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104-112.
20. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-209.
21. 14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-1322.
22. Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28 149-167.
23. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994; 26: 7-15.
24. Ding PY, Chu KM, Chiang HT, Shu KH. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 58: 16-22.
25. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: Meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-117.
26. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Am J Hypertens 1999; 12: 1181-1187.
27. Ragot S, Ezzaher A, Meunier A, Poterre M, Bourkaib R, Herpin D. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16: 865-873.
28. Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy. Clin Exp Hypertens 2005; 27: 129-138.
29. Redón J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: The ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoring. Blood Press Monit 2002; 7: 111-116.
30. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415.
31. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
32. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
33. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database. J Clin Hypertens 2003; 5: 58-63.
34. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43 10-17.
35. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21: 1291-1298.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.